Skip to content

Study · Systematic review · 2026

8 results

Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.

Parizad R, Hatwal J, Taban Sadeghi M, Brar A, Desai R, Batta A, Mohan B

Vascular health and risk management10 Mar 2026Cited by 8 (Europe PMC)

PMID41953528 (opens in a new tab)PMCIDPMC13054715 (opens in a new tab)DOI10.2147/vhrm.s578698 (opens in a new tab)PepBankPUB-41953528
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, semaglutide (STEP-HFpEF program) was reported to improve symptoms in obesity-associated phenotypes.

    In plain wordsA review reports that semaglutide improved symptoms in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Semaglutide
    Outcome
    Not applicableSymptoms in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  2. 02HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, semaglutide (STEP-HFpEF program) was reported to improve exercise capacity in obesity-associated phenotypes.

    In plain wordsA review reports that semaglutide improved exercise capacity in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Semaglutide
    Outcome
    IncreaseExercise capacity in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  3. 03HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, semaglutide (STEP-HFpEF program) was reported to reduce weight in obesity-associated phenotypes.

    In plain wordsA review reports that semaglutide reduced weight in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight reduction in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  4. 04HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, semaglutide (STEP-HFpEF program) was reported to improve composite CV or HF outcomes in obesity-associated phenotypes.

    In plain wordsA review reports that semaglutide improved combined heart outcomes in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Semaglutide
    Outcome
    DecreaseComposite CV or HF outcomes in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  5. 05HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, tirzepatide (SUMMIT trial) was reported to improve symptoms in obesity-associated phenotypes.

    In plain wordsA review reports that tirzepatide improved symptoms in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Tirzepatide
    Outcome
    Not applicableSymptoms in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  6. 06HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, tirzepatide (SUMMIT trial) was reported to improve exercise capacity in obesity-associated phenotypes.

    In plain wordsA review reports that tirzepatide improved exercise capacity in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Tirzepatide
    Outcome
    IncreaseExercise capacity in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  7. 07HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, tirzepatide (SUMMIT trial) was reported to reduce weight in obesity-associated phenotypes.

    In plain wordsA review reports that tirzepatide reduced weight in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight reduction in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.
  8. 08HumanSystematic reviewEfficacy outcome

    In a systematic review of HFpEF, tirzepatide (SUMMIT trial) was reported to improve composite CV or HF outcomes in obesity-associated phenotypes.

    In plain wordsA review reports that tirzepatide improved combined heart outcomes in people with obesity-linked heart failure with preserved ejection fraction.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite CV or HF outcomes in obesity-associated HFpEF
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, incretin-based therapies such as semaglutide (STEP-HFpEF program) and tirzepatide (SUMMIT trial) have shown clinically meaningful improvements in symptoms, exercise capacity, weight reduction, and composite CV or HF outcomes, notably in obesity-associated HFpEF phenotypes.
    2 context sentences
    Summary · context
    A comprehensive systematic literature search was conducted using PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025.
    Summary · context
    Eligible studies included randomized controlled trials (RCTs), observational cohort studies, systematic reviews, meta-analyses, and current clinical guidelines talking key aspects of HFpEF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.